About Xellera Therapeutics Asia Limited
Xellera Therapeutics Asia LimitedNovoheart is a global stem cell biotechnology company that is dedicated to develop and engineer bio-artificial human heart prototypes using a combination of world’s first and state-of-the-art stem cell and tissue engineering approaches. Our mission and vision are to revolutionize drug discovery and development of heart therapeutics with our range of proprietary bio-engineered human heart constructs , and to further develop them into transplantable heart grafts for cell-based regenerative therapies with superior safety and efficacy.
